Vical: Allovectin P3 Results Conference Call (Vical) - Nov 21, 2013 - "DTIC/TMZ was more effective than velimogene aliplasmid for best overall response rate at ≥24 weeks in this trial"; "Overall survival was not significantly different with velimogene aliplasmid than with DTIC/TMZ in this trial"; "The responses with velimogene aliplasmid were more durable than with DTIC/TMZ in this trial: Median OS (mos.) was greater for velimogene aliplasmid responders [n/a (19.7, n/a)] than for DTIC/TMZ responders [40.7 (28.9, n/a)], A substantial majority (83%) of velimogene aliplasmid responders were still alive at last contact"; "Follow-on treatments may have had an effect on overall survival" "
P3 data • Melanoma
|